News Releases
The Company announced that its Board has appointed CEO René Lerer, M.D. to the additional role of chairman of the board, effective immediately. The Board also elected
Financial Results
For the fiscal year ended
For the fourth quarter of 2008, the Company reported net revenue of
See the attached tables detailing the Company’s operating results, including results by segment.
The Company ended the quarter with unrestricted cash and investments of
René Lerer, M.D., chairman and CEO, said, “The Company turned in another strong, full-year financial performance in 2008 and I am very pleased with the results. Our business segments performed well, with particular strength in our key growth areas of public sector behavioral health, specialty pharmacy and radiology. Demonstrating our success in diversifying our earnings by expanding into high-trend specialty areas where we can leverage our expertise and add value, specialty pharmacy and radiology represented 20 percent of both our revenues and segment profit in 2008 prior to corporate overhead.”
“In our behavioral business, we generated strong results across the public sector segment, including the impact of a full year of the Maricopa County contract. In the commercial segment, our results were affected by the previously disclosed loss of certain contracts, as well as higher than expected care costs associated with a portion of a large risk contract. That said, I am pleased to note that, during the fourth quarter, we extended one of our larger commercial contracts for an additional two years through
Rubin added, “We have made excellent progress on our share repurchase program, which we announced last summer. Through
Outlook
Management reiterated its expectation that, for fiscal 2009, the Company will generate net revenue in the range of
Lerer commented, “As we enter 2009, I am pleased to announce two new relationships that demonstrate progress on our growth efforts. First, we recently signed a new risk radiology contract, which we are currently implementing with a go-live date of
“In addition, in the specialty pharmacy arena, on
“As we move ahead, our focus is on continued profitable growth and retention of key customers. This effort comprises many objectives including continued excellent service to customers, consumers and providers; new business initiatives across our existing and emerging businesses; stabilization and growth of our core businesses; diversification across customer and business lines; and a continued focus on exploring capital deployment activity in a thoughtful, strategic manner,” Lerer said.
Board of Directors Update
The Board of Directors of the Company elected
Broshy is executive chairman of the board of
The Company also announced that
Commenting on behalf of the Board, Lead Director
“I’m honored to have the opportunity to lead the Board as chairman and appreciate the confidence the Board has shown in me,” Lerer said. “I also am pleased to welcome
“I also want to recognize and thank
Earnings Results Conference Call
Management will host a conference call at
The conference call also will be available via a live Webcast at Magellan's investor relations page at www.MagellanHealth.com.
A taped replay of the conference call will be available for one week following the call. Interested parties should call 888-673-3574 or 402-220-6437(from outside the U.S.).
Those who plan to access the call or Webcast are encouraged to read Magellan's Annual Report on Form 10-K for the year ended
About Magellan: Headquartered in
Cautionary Statement: This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, that involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2009 net revenue, net income, segment profit, and earnings per share. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the Company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the Company by customers and/or providers; higher utilization of health care services by the Company’s risk members; delays, higher costs or inability to implement new business or other Company initiatives; the impact of changes in the contracting model for
|
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES |
|||||||||||||||||
|
Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||||
|
2007 |
2008 (1) |
2007 |
2008 (1) |
||||||||||||||
|
(unaudited) |
(unaudited) | ||||||||||||||||
| Net revenue | $ | 658,005 | $ | 661,784 | $ | 2,155,953 | $ | 2,625,394 | |||||||||
| Cost and expenses: | |||||||||||||||||
| Cost of care | 452,058 | 461,794 | 1,409,103 | 1,830,542 | |||||||||||||
| Cost of goods sold | 41,533 | 46,838 | 149,585 | 181,356 | |||||||||||||
| Direct service costs and other operating expenses (2) | 105,521 | 104,517 | 404,003 | 426,627 | |||||||||||||
| Depreciation and amortization | 15,974 | 15,827 | 57,524 | 60,810 | |||||||||||||
| Interest expense | 1,359 | 22 | 6,386 | 2,846 | |||||||||||||
| Interest income | (6,696 | ) | (3,694 | ) | (23,836 | ) | (17,030 | ) | |||||||||
| 609,749 | 625,304 | 2,002,765 | 2,485,151 | ||||||||||||||
|
Income from continuing operations before income taxes and minority interest |
48,256 | 36,480 | 153,188 | 140,243 | |||||||||||||
| Provision for income taxes | 16,739 | 12,896 | 58,669 | 54,038 | |||||||||||||
| Income from continuing operations before minority interest | 31,517 | 23,584 | 94,519 | 86,205 | |||||||||||||
| Minority interest, net | 216 | - | 361 | - | |||||||||||||
| Net income | 31,301 | 23,584 | 94,158 | 86,205 | |||||||||||||
| Other comprehensive income (loss) | (9 | ) | 2,013 | 31 | 147 | ||||||||||||
| Comprehensive income | $ | 31,292 | $ | 25,597 | $ | 94,189 | $ | 86,352 | |||||||||
| Weighted average number of common shares outstanding — basic | 39,485 | 38,464 | 38,942 | 39,607 | |||||||||||||
| Weighted average number of common shares outstanding — diluted | 40,380 | 38,631 | 39,837 | 39,999 | |||||||||||||
| Net income per common share — basic | $ | 0.79 | $ | 0.61 | $ | 2.42 | $ | 2.18 | |||||||||
| Net income per common share — diluted | $ | 0.78 | $ | 0.61 | $ | 2.36 | $ | 2.16 | |||||||||
|
(1) For a more detailed discussion of Magellan's results for the year ended December 31, 2008, refer to the Company's Annual Report on Form 10-K that will be filed with the SEC on February 27, 2009, and the live broadcast or taped replay of the Company's earnings conference call on February 27, 2009 that will be available at www.MagellanHealth.com. |
|||||||||||||||||
|
(2) Includes stock compensation expense of $7,332 and $6,414 for the three months ended December 31, 2007 and 2008, respectively, and $29,994 and $32,763 for the years ended December 31, 2007 and 2008, respectively. |
|||||||||||||||||
|
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES |
|||||||||
| Year Ended December 31, | |||||||||
| 2007 | 2008 | ||||||||
|
Cash flows from operating activities: |
|||||||||
| Net income | $ | 94,158 | $ | 86,205 | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Depreciation and amortization | 57,524 | 60,810 | |||||||
| Non-cash interest expense | 2,681 | 1,423 | |||||||
| Non-cash stock compensation expense | 29,994 | 32,763 | |||||||
| Non-cash income tax expense | 38,677 | 42,241 | |||||||
|
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses: |
|||||||||
| Restricted cash | (111,731 | ) | 60,368 | ||||||
| Accounts receivable, net | 2,707 | (15,720 | ) | ||||||
| Other assets | (5,233 | ) | (9,290 | ) | |||||
| Accounts payable and accrued liabilities | 15,056 | 11,519 | |||||||
| Medical claims payable and other medical liabilities | 69,824 | (426 | ) | ||||||
| Other | 906 | (1,589 | ) | ||||||
| Net cash provided by operating activities | 194,563 | 268,304 | |||||||
| Cash flows from investing activities: | |||||||||
| Capital expenditures | (47,553 | ) | (36,314 | ) | |||||
| Acquisitions and investments in businesses, net of cash acquired | (17,790 | ) | (25,425 | ) | |||||
| Purchase of investments | (133,643 | ) | (404,420 | ) | |||||
| Maturity of investments | 134,367 | 228,392 | |||||||
| Net cash used in investing activities | (64,619 | ) | (237,767 | ) | |||||
| Cash flows from financing activities: | |||||||||
| Payments on long-term debt and capital lease obligations | (27,855 | ) | (13,981 | ) | |||||
| Payments to acquire treasury stock | - | (136,153 | ) | ||||||
| Proceeds from exercise of stock options and warrants | 32,403 | 12,896 | |||||||
| Tax benefit from exercise of stock options | 14,357 | 7,549 | |||||||
| Other | (214 | ) | (1,395 | ) | |||||
| Net cash provided by (used in) financing activities | 18,691 | (131,084 | ) | ||||||
| Net increase (decrease) in cash and cash equivalents | 148,635 | (100,547 | ) | ||||||
| Cash and cash equivalents at beginning of period | 163,737 | 312,372 | |||||||
| Cash and cash equivalents at end of period | $ | 312,372 | $ | 211,825 | |||||
|
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES |
|||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||
| 2007 | 2008 | 2007 | 2008 | ||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||
| Net revenue | |||||||||||||||||
| - Commercial | $ | 194,273 | $ | 162,844 | $ | 784,533 | $ | 649,636 | |||||||||
| - Public Sector | 345,136 | 367,115 | 1,020,839 | 1,451,923 | |||||||||||||
| - Radiology Benefits Management | 68,995 | 71,446 | 170,240 | 295,336 | |||||||||||||
| - Specialty Pharmaceutical Management | 49,601 | 60,379 | 180,341 | 228,499 | |||||||||||||
| Total revenue | 658,005 | 661,784 | 2,155,953 | 2,625,394 | |||||||||||||
| Cost of care | |||||||||||||||||
| - Commercial | 93,387 | 92,192 | 392,325 | 344,761 | |||||||||||||
| - Public Sector | 304,143 | 314,942 | 902,594 | 1,278,316 | |||||||||||||
| - Radiology Benefits Management | 54,528 | 54,660 | 114,184 | 207,465 | |||||||||||||
| Total cost of care | 452,058 | 461,794 | 1,409,103 | 1,830,542 | |||||||||||||
| Cost of goods sold - Specialty Pharmaceutical Management | 41,533 | 46,838 | 149,585 | 181,356 | |||||||||||||
| Direct service costs | |||||||||||||||||
| - Commercial | 40,756 | 41,306 | 163,800 | 154,894 | |||||||||||||
| - Public Sector | 16,907 | 17,779 | 51,922 | 68,914 | |||||||||||||
| - Radiology Benefits Management | 12,521 | 13,074 | 48,841 | 54,482 | |||||||||||||
| - Specialty Pharmaceutical Management | 5,796 | 6,859 | 21,529 | 25,623 | |||||||||||||
| Total direct services costs | 75,980 | 79,018 | 286,092 | 303,913 | |||||||||||||
| Other operating expenses - Corporate & Other | 29,541 | 25,499 | 117,911 | 122,714 | |||||||||||||
| Stock compensation expense (1) | |||||||||||||||||
| - Commercial | (582 | ) | (271 | ) | (2,277 | ) | (1,368 | ) | |||||||||
| - Public Sector | (402 | ) | (241 | ) | (1,172 | ) | (839 | ) | |||||||||
| - Radiology Benefits Management | (38 | ) | (376 | ) | (1,708 | ) | (1,472 | ) | |||||||||
| - Specialty Pharmaceutical Management | (2,286 | ) | (2,522 | ) | (8,769 | ) | (8,967 | ) | |||||||||
| - Corporate & Other | (4,024 | ) | (3,004 | ) | (16,068 | ) | (20,117 | ) | |||||||||
| Total stock compensation expense | (7,332 | ) | (6,414 | ) | (29,994 | ) | (32,763 | ) | |||||||||
| Segment profit (loss) | |||||||||||||||||
| - Commercial | 60,712 | 29,617 | 230,685 | 151,349 | |||||||||||||
| - Public Sector | 24,488 | 34,635 | 67,495 | 105,532 | |||||||||||||
| - Radiology Benefits Management | 1,984 | 4,088 | 8,923 | 34,861 | |||||||||||||
| - Specialty Pharmaceutical Management | 4,558 | 9,204 | 17,996 | 30,487 | |||||||||||||
| - Corporate & Other | (25,517 | ) | (22,495 | ) | (101,843 | ) | (102,597 | ) | |||||||||
| Total segment profit | $ | 66,225 | $ | 55,049 | $ | 223,256 | $ | 219,632 | |||||||||
|
Reconciliation of segment profit to income from continuing operations before income taxes and minority interest: |
|||||||||||||||||
| Segment profit | $ | 66,225 | $ | 55,049 | $ | 223,256 | $ | 219,632 | |||||||||
| Stock compensation expense | (7,332 | ) | (6,414 | ) | (29,994 | ) | (32,763 | ) | |||||||||
| Depreciation and amortization | (15,974 | ) | (15,827 | ) | (57,524 | ) | (60,810 | ) | |||||||||
| Interest expense | (1,359 | ) | (22 | ) | (6,386 | ) | (2,846 | ) | |||||||||
| Interest income | 6,696 | 3,694 | 23,836 | 17,030 | |||||||||||||
|
Income from continuing operations before income taxes and minority interest |
$ | 48,256 | $ | 36,480 | $ | 153,188 | $ | 140,243 | |||||||||
| Membership | |||||||||||||||||
| - Commercial | 39.4 | ||||||||||||||||
| - Public Sector | 2.1 | ||||||||||||||||
| - Radiology Benefits Management | 16.5 | ||||||||||||||||
| Total membership | 58.0 | ||||||||||||||||
|
(1) Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis. |
|||||||||||||||||
Source:
Magellan Health Services, Inc.
Investor:
Renie Shapiro, 877-645-6464
or
Media:
Erin Somers, 410-953-2405
